AWK: Data curation, Investigation, Supervision, Writing—original draft, Writing—review & editing. SC: Data curation, Writing—original draft, Writing—review & editing. HM: Data curation, Writing—original draft, Writing—review & editing. JS: Conceptualization, Project administration, Supervision, Writing—review & editing. BP: Data curation, Visualization, Writing—original draft, Writing—review & editing. DB: Conceptualization, Supervision, Validation, Writing—review & editing. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical approval
This case series report was deemed exempt from Institutional Review Board (IRB) review by the Saint Luke’s Health System (SLHS) IRB under federal regulations (45CFR46.102(d) and 45CFR164.501) as it involves data from three or fewer patients and is not considered a systematic investigation designed to contribute to generalizable knowledge.
Nonetheless, the authors affirm that all procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki.
Consent to participate
Informed consent was obtained from the patient for writing this manuscript as well as accompanying images.
Consent to publication
Not applicable.
Availability of data and materials
The patient’s data is available through Saint Luke’s Hospital electronic medical records. More information can be obtained by contacting the corresponding author.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
Henter JI, Aricò M, Egeler RM, Elinder G, Favara BE, Filipovich AH, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society.Med Pediatr Oncol. 1997;28:342–7. [DOI] [PubMed]
Takahashi H, Koiwa T, Fujita A, Suzuki T, Tagashira A, Iwasaki Y. A case of pembrolizumab-induced hemophagocytic lymphohistiocytosis successfully treated with pulse glucocorticoid therapy.Respir Med Case Rep. 2020;30:101097. [DOI] [PubMed] [PMC]
Mizuta H, Nakano E, Takahashi A, Koyama T, Namikawa K, Yamazaki N. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.Dermatol Ther. 202;33:e13321. [DOI] [PubMed]
Sadaat M, Jang S. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.J Immunother Cancer. 2018;6:49. [DOI] [PubMed] [PMC]
Dupré A, Michot JM, Schoeffler A, Frumholtz L, Baroudjian B, Delyon J, et al. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.Br J Haematol. 2020;189:985–92. [DOI] [PubMed]
Li X, Shao C, Shi Y, Han W. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.J Hematol Oncol. 2018;11:31. [DOI] [PubMed] [PMC]
Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer. 200;48:124–31. [DOI] [PubMed]
Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.Arthritis Rheumatol. 2014;66:2613–20. [DOI] [PubMed]
von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.Clin Chem. 2020;66:779–93. [DOI] [PubMed] [PMC]
Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.Cancer Immunol Res. 2018;6:1093–9. [DOI] [PubMed] [PMC]
